IP Library Granted Patent US 10,294,274
Granted Patent B2
US 10,294,274 · App. 15/029,248 · Granted May 21, 2019

Polypeptide ligands specific for plasma kallikrein

Inventors: Daniel Teufel (Cambridge, GB); Catherine Stace (Cambridge, GB); Edward Walker (Cambridge, GB)
Assignee: BicycleRD Limited
C07K7/64C07K7/08C07K17/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,294,274
App. No.
15/029,248
Granted
May 21, 2019
Kind
B2
Abstract

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are specific for the human and rat protease plasma kallikrein and are modified in one or two peptide loops to enhance potency and/or protease resistance.

Claims (28)

1. A peptide ligand specific for plasma kallikrein comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises a peptide sequence selected from any of:

((06-550) HArg5)

(SEQ ID NO: 56)

-C i -S-F-P-Y-[hR]-C ii -V-Y-Y-P-D-I-C iii -;

(SEQ ID NO: 57)

-C i -S-F-[Aze]-Y-R-C ii -V-Y-Y-P-D-I-C iii ;

((06-550) Aze3 HArg5)

(SEQ ID NO: 58)

-C i -S-F-[Aze]-Y-[hR]-C ii -V-Y-Y-P-D-I-C iii -;

((06-550) NMeArg5)

(SEQ ID NO: 59)

-C i -S-F-P-Y-[NMeR]-C ii -V-Y-Y-P-D-I-C iii -;

((06-550) Aze3 NMeArg5)

(SEQ ID NO: 60)

-C i -S-F-[Aze]-Y-[NMeR]-C ii -V-Y-Y-P-D-I-C iii -;

((06-259-02 (Sar 3 -(D-Arg) 2 )

(SEQ ID NO: 61)

-C i -N-T-W-N-P-W-C ii -P-W-D-A-P-L-C iii -A-Sar 3 -(D-Arg) 2 ;

((06-550)-Sar 3 -(DArg 2 ))

(SEQ ID NO: 62)

-C i -S-F-P-Y-R-C ii -V-Y-Y-P-D-I-C iii -A-Sar 3 -(D-Arg) 2 ;

and

((06-550)-Sar 3 -(DArg 2 ) Aze3 HArg5)

(SEQ ID NO: 63)

-C i -S-F-[Aze]-Y-[hR]-C ii -V-Y-Y-P-D-I-C iii -A-Sar 3 -

(D-Arg) 2 ;

wherein Aze represents an L-azetidine carboxylic acid residue, hR and HArg represents an L-homoarginine residue, NMeR and NMeArg represents an N-α-methyl arginine residue, Sar 3 represents 3 sarcosine spacers and (D-Arg) 2 represents 2 D-arginine residues.

2. The peptide ligand of claim 1 , comprising a peptide sequence of -C i -S-F-[Aze]-Y-[hR]-C iii -V—Y-Y-P-D-1-C iii -A-Sar 3 -(D-Arg) 2 ((06-550)-Sar 3 -(DArg 2 ) Aze3 HArg5) (SEQ ID NO: 63).

Assignments (2)
CHANGE OF NAME Recorded Jan 31, 2018
From: BICYCLE THERAPEUTICS LIMITED (GB/GB)
To: BICYCLERD LIMITED
Reel/Frame 044793/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2017
From: TEUFEL, DANIEL; STACE, CATHERINE; WALKER, EDWARD
To: BICYCLE THERAPEUTICS LIMITED
Reel/Frame 042056/0673 →
Priority Claims (2)
GB 1318941.0 · Oct 28, 2013 · national
GB 1410265.1 · Jun 10, 2014 · national
Continuity (1)
Related Publication 20160222063A1 · Aug 4, 2016
Cited By (15)
US 12,318,454 US 12,350,343 US 12,377,155 US 12,378,288 US 12,435,107 US 12,459,974 US 12,491,253 US 12,492,224 US 12,516,084 US 12,540,161 US 12,551,567 US 12,552,837 US 12,570,695 US 12,606,594 US 12,630,588